FrancophonIA/ELRC3.0 huggingface dataset:
English: The product should not be used by persons with a hypersensitivity to the active substance or to any of the excipients (see contraindications, section 4.3).
Estonian: Inimesed, kes on ülitundlikud toimeaine või ükskõik millise abiaine suhtes, ei tohi ravimit kasutada (vt Vastunäidustused lõik 4.3).
English: Fluralaner has a high potency against ticks and fleas by exposure via feeding, i.e. it is systemically active on target parasites.
Estonian: Fluralaneer avaldab toitumise kaudu kokkupuutel tõhusat toimet puukide ja kirpude vastu s.t see avaldab sihtparasiitidele süsteemset toimet.
English: Safety was demonstrated in breeding, pregnant and lactating animals treated with overdoses of up to 3 times the maximum recommended dose.
Estonian: Ohutust näidati aretuses kasutatavatel, tiinetel ja lakteerivatel koertel üleannustega, mis kuni kolm korda ületasid maksimaalseid soovitatavaid annuseid.
English: Each pipette delivers:
Estonian: Iga pipett sisaldab:
English: Dimethylacetamide Glycofurol
Estonian: Dimetüülatsetamiid Glükofurool
English: Convulsions and lethargy has been reported very rarely in spontaneous (pharmacovigilance) reports.
Estonian: Spontaansetes (ravimiohutuse järelevalve) aruannetes on väga harva teatatud krampidest ja letargiast.
English: In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.
Estonian: Juhuslikul ravimi allaneelamisel pöörduda viivitamatult arsti poole ja näidata pakendi infolehte või pakendi etiketti.
English: The prolonged persistence and slow elimination from plasma (t1/2 = 12 days) and the lack of extensive metabolism provide effective concentrations of fluralaner for the duration of the inter-dosing interval.
Estonian: Pikendatud toimeaeg ja aeglane eritumine plasmast (t1/2 = 12 päeva) ning ekstensiivse metabolismi puudumine tagavad fluralaneeri efektiivse kontsentratsiooni annuste vahelise intervalli kestel.
English: Do not use this veterinary medicinal product after the expiry date stated on the packaging after EXP.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud pakendil pärast EXP. Kõlblikkusaeg viitab selle kuu viimasele päevale.
English: The product should not be used by persons with a hypersensitivity to the active substance or to any of the excipients (see section Contraindications).
Estonian: Inimesed, kes on ülitundlikud toimeaine või ükskõik millise abiaine suhtes, ei tohi toodet kasutada (vt lõik Vastunäidustused).
English: for small cats 1.2 - 2.8 kg for medium-sized cats >2.8 - 6.25 kg for large cats >6.25 - 12.5 kg
Estonian: väikestele kassidele 1,2-2,8 kg keskmise suurusega kassidele > 2,8-6,25 kg suurtele kassidele > 6,25-12,5 kg
English: Wash hands thoroughly with soap and water immediately after use of the product.
Estonian: Koheselt pärast preparaadi kasutamist pesta käsi hoolikalt seebi ja veega.
English: Hypersensitivity reactions to the product have been reported in a small number of people.
Estonian: Väikesel osal inimestest on esinenud ülitundlikkusreaktsioone ravimi suhtes.
English: 1 x 0.4 ml 1 x 0.89 ml 1 x 1.79 ml 1 x 3.57 ml 1 x 5.0 ml 2 x 0.4 ml 2 x 0.89 ml 2 x 1.79 ml 2 x 3.57 ml 2 x 5.0 ml
Estonian: 1 × 0,4 ml 1 × 0,89 ml 1 × 1,79 ml 1 × 3,57 ml 1 × 5,0 ml 2 × 0,4 ml 2 × 0,89 ml 2 × 1,79 ml 2 × 3,57 ml 2 × 5,0 ml
English: The prolonged persistence and slow elimination from plasma (t1/2 = 21 days) and the lack of extensive metabolism provide effective concentrations of fluralaner for the duration of the inter-dosing interval.
Estonian: Kauakestev püsivus, aeglane eritumine plasmast (t1/2 = 21 päeva) ja ekstensiivse metabolismi puudumine tagavad fluralaneeri efektiivse kontsentratsiooni annustamistevahelisel perioodil.
English: If skin contact does occur, wash the affected area immediately with soap and water.
Estonian: Ravimi sattumisel nahale peske ravimiga kokkupuutunud piirkonda viivitamata vee ja seebiga.
English: For the treatment of tick and flea infestations in cats.
Estonian: Puugi- ja kirbuinfestatsioonide raviks kassidel.
English: Interaction with other medicinal products and other forms of interaction: None known.
Estonian: Koostoimed teiste ravimitega ja muud koostoimed
English: Intervet International B. V. Wim de Körverstraat 35 5831 AN Boxmeer The NETHERLANDS
Estonian: Intervet International B. V. Wim de Körverstraat 35 5831 AN Boxmeer HOLLAND
English: Bravecto chewable tablets
Estonian: Bravecto närimistabletid
English: EU/2/13/158/001 EU/2/13/158/002 EU/2/13/158/003 EU/2/13/158/004 EU/2/13/158/005 EU/2/13/158/006 EU/2/13/158/007 EU/2/13/158/008 EU/2/13/158/009 EU/2/13/158/010 EU/2/13/158/011 EU/2/13/158/012 EU/2/13/158/013
Estonian: EU/2/13/158/001 EU/2/13/158/002 EU/2/13/158/003 EU/2/13/158/004 EU/2/13/158/005 EU/2/13/158/006 EU/2/13/158/007 EU/2/13/158/008 EU/2/13/158/009 EU/2/13/158/010 EU/2/13/158/011 EU/2/13/158/012
English: Pregnancy, lactation and fertility: The veterinary medicinal product can be used in breeding, pregnant and lactating dogs.
Estonian: Tiinus, laktatsioon, sigimisfunktsioon Seda veterinaarravimit on lubatud kasutada aretuses kasutatavatel, tiinetel ja lakteerivatel koertel.
English: Bravecto should be administered in accordance with the following table (corresponding to a dose of 40 - 94 mg fluralaner/kg body weight):
Estonian: Bravectot tuleb manustada alltoodud tabeli järgi (vastavalt annusele 40-94 mg fluralaneeri kg kehamassi kohta):
English: In the absence of available data, this veterinary medicinal product should not be used on kitten less than 11 weeks old and /or cats weighing less than 1.2 kg.
Estonian: Olemasolevate andmete puudumise tõttu ei tohi seda veterinaarravimit kasutada alla 11 nädala vanustel kassipoegadel ja/või alla 1,2 kg kehamassiga kassidel.
English: For cats above 12.5 kg body weight, use a combination of two pipettes that most closely matches the body weight.
Estonian: Kasside jaoks kehamassiga üle 12,5 kg kasutage kahe pipeti kombinatsiooni, mis vastab kõige täpsemini kehamassile.
English: Marketing authorisation holder: Intervet International B. V.
Estonian: Intervet International B. V.
English: Pregnancy, lactation and fertility: Can be used in breeding, pregnant and lactating dogs.
Estonian: Tiinus, laktatsioon ja fertiilsus Lubatud kasutada aretuses kasutatavatel, tiinetel ja lakteerivatel koertel.
English: For dogs above 56 kg bodyweight, use a combination of two tablets that most closely matches the bodyweight.
Estonian: Koertele kehamassiga üle 56 kg kasutada kahe tableti kombinatsiooni, mis kõige täpsemini vastab koera kehamassile.
English: 1 x 0.4 ml 1 x 0.89 ml 1 x 1.79 ml 2 x 0.4 ml 2 x 0.89 ml 2 x 1.79 ml
Estonian: 1 × 0,4 ml 1 × 0,89 ml 1 × 1,79 ml 2 × 0,4 ml 2 × 0,89 ml 2 × 1,79 ml
English: The twist-anduse cap should be rotated clockwise or counter clockwise one full turn.
Estonian: Korki tuleb keerata päripäeva või vastupäeva üks terve ring.
English: Shelf life of the veterinary medicinal product as packaged for sale: Bravecto 112.5 mg spot-on solution: 2 years Bravecto 250 mg / 500 mg spot-on solution: 3 years
Estonian: Müügipakendis veterinaarravimi kõlblikkusaeg: Bravecto 112,5 mg täpilahus: 2 aastat.
English: 112.5 mg fluralaner 250 mg fluralaner 500 mg fluralaner
Estonian: 112,5 mg fluralanerum 250 mg fluralanerum 500 mg fluralanerum
English: The onset of efficacy is within 12 hours for fleas (C. felis) and within 48 hours for ticks (I. ricinus).
Estonian: Toime kirpude (C. felis) vastu saabub 12 tunni jooksul ja puukide (I. ricinus) vastu 48 tunni jooksul.
English: The pipette is open and ready for application when the breaking of the seal is felt.
Estonian: Kui on tunda tihendi murdumist, on pipett avatud ja manustamiseks valmis.
English: In order to avoid contact, disposable protective gloves obtained with this product at the point of sale must be worn when handling and administering the product.
Estonian: Ravimi nahale sattumise vältimiseks tuleb toote käsitsemisel ja manustamisel kanda selle toote ostmisel hangitud ühekordseid kaitsekindaid.
English: Cardboard box with 1 aluminium foil blister sealed with PET aluminium foil lid stock containing 1, 2 or 4 chewable tablets.
Estonian: Pappkarp, milles on 1 alumiiniumfooliumist blister, mis on suletud polüetüleentereftalaadist (PET) / alumiiniumist valmistatud kattega.
English: Bravecto 112.5 mg (2-4.5 kg) Bravecto 250 mg (>4.5 -10 kg) Bravecto 500 mg (>10 -20 kg) Bravecto 1,000 mg (>20 -40 kg) Bravecto 1,400 mg (>40 -56 kg) fluralaner
Estonian: Bravecto 112,5 mg (2-4,5 kg) Bravecto 250 mg (> 4,5-10 kg) Bravecto 500 mg (> 10-20 kg) Bravecto 1000 mg (> 20-40 kg) Bravecto 1400 mg (> 40-56 kg)
English: The dog should be observed during administration to confirm that the tablet is swallowed.
Estonian: Tableti alla neelamises veendumiseks tuleb koera manustamise ajal jälgida.
English: For dogs above 56 kg body weight, use a combination of two pipettes that most closely matches the body weight.
Estonian: Koerte jaoks kehamassiga üle 56 kg kasutage kahe pipeti kombinatsiooni, mis vastab kõige täpsemini kehamassile.
English: Bravecto should be administered in accordance with the following table (corresponding to a dose of 25-56 mg fluralaner/kg bodyweight within one weight band):
Estonian: Bravecto manustamine peab toimuma vastavalt järgnevale tabelile (vastates annusele 25-56 mg fluralaneeri/kg kehamassi kohta ühes kaaluvahemikus):
English: For the treatment of tick and flea infestations on dogs.
Estonian: Puugi- ja kirbuinfestatsioonide raviks koertel.
English: The veterinary medicinal product was well tolerated in Collies with a deficient multidrug-resistanceprotein 1 (MDR1 -/-) following single oral administration at 3 times the recommended dose (168 mg/kg bodyweight).
Estonian: Defektse multiravimiresistentse proteiiniga 1 (MDR1 -/-) kollid talusid veterinaarravimit hästi pärast ühekordset 3-kordses soovitatud annuses (168 mg/kg kehamassi kohta) suukaudset manustamist.
English: No adverse reactions were observed following topical administration to puppies aged 8-9 weeks and weighing 2.0-3.7 kg treated with overdoses of up to 5 times the maximum recommended dose (56 mg, 168 mg and 280 mg fluralaner/kg bodyweight) on three occasions at shorter intervals than recommended (8-week intervals).
Estonian: Kõrvaltoimeid ei täheldatud pärast ravimi üleannustes suukaudset manustamist 8-9-nädala vanustele ja 2,0-3,6 kg kaaluvatele kutsikatele kuni 5-kordsetes maksimaalsetes soovituslikes annustes (56 mg, 168 mg ja 280 mg fluralaneeri/kg kehamassi kohta) kolmel juhul soovituslikest intervallidest (8nädalat) lühemate intervallidega.
English: Fluralaner 112.5 mg Fluralaner 250 mg Fluralaner 500 mg Fluralaner 1,000 mg Fluralaner 1,400 mg
Estonian: Fluralanerum 112,5 mg Fluralanerum 250 mg Fluralanerum 500 mg Fluralanerum 1000 mg Fluralanerum 1400 mg
English: This veterinary medicinal product is a systemic insecticide and acaricide that provides immediate and persistent flea (Ctenocephalides felis) and tick (Ixodes ricinus) killing activity for 12 weeks.
Estonian: See veterinaarravim on süsteemne insektitsiid ja akaritsiid, millel on kohene ning püsiv kirpe (Ctenocephalides felis) ja puuke (Ixodes ricinus) surmav toime 12 nädala jooksul.
English: Safety was demonstrated in puppies aged 8-9 weeks and weighing 2.0-3.6 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
Estonian: Ohutust demonstreeriti ravimi üleannustes manustamisel 8-9-nädala vanustele ja 2,0-3,6 kg kaaluvatele kutsikatele kuni 5-kordsetes maksimaalsetes soovituslikes annustes kolmel korral soovituslikest intervallidest (8-nädalat) lühemate intervallidega.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - Väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - Sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - Aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - Harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10 000-st ravitud loomast) - Väga harv (vähem kui 1-l loomal 10 000-st ravitud loomast, kaasaarvatud üksikjuhud).
English: During clinical field testing, no interactions between Bravecto chewable tablets for dogs and routinely used veterinary medicinal products were observed.
Estonian: Välitingimustes läbiviidud kliinilistes uuringutes ei täheldatud koostoimeid koertele mõeldud Bravecto närimistablettide ja tavakasutuses olevate veterinaarravimite vahel.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports)
Estonian: Kõrvaltoimete sagedus on defineeritud järgnevalt: - Väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - Sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - Aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - Harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10 000-st ravitud loomast) - Väga harv (vähem kui 1-l loomal 10 000-st ravitud loomast, kaasaarvatud üksikjuhud)
English: 112.5 mg fluralaner 250 mg fluralaner 500 mg fluralaner 1,000 mg fluralaner 1,400 mg fluralaner
Estonian: 112,5 mg fluralanerum 250 mg fluralanerum 500 mg fluralanerum 1000 mg fluralanerum 1400 mg fluralanerum
English: EU/2/13/158/016 (112.5 mg, 1 pipette) EU/2/13/158/017 (112.5 mg, 2 pipettes) EU/2/13/158/020 (250 mg, 1 pipette) EU/2/13/158/021 (250 mg, 2 pipettes) EU/2/13/158/024 (500 mg, 1 pipette) EU/2/13/158/025 (500 mg, 2 pipettes) EU/2/13/158/028 (1,000 mg, 1 pipette) EU/2/13/158/029 (1,000 mg, 2 pipettes) EU/2/13/158/030 (1,400 mg, 1 pipette) EU/2/13/158/031 (1,400 mg, 2 pipettes)
Estonian: EU/2/13/158/016 (112,5 mg, 1 pipett) EU/2/13/158/017 (112,5 mg, 2 pipetti) EU/2/13/158/020 (250 mg, 1 pipett) EU/2/13/158/021 (250 mg, 2 pipetti) EU/2/13/158/024 (500 mg, 1 pipett) EU/2/13/158/025 (500 mg, 2 pipetti) EU/2/13/158/028 (1000 mg, 1 pipett) EU/2/13/158/029 (1000 mg, 2 pipetti) EU/2/13/158/030 (1400 mg, 1 pipett) EU/2/13/158/031 (1400 mg, 2 pipetti)
English: EU/2/13/158/018 (112.5 mg, 1 pipette) EU/2/13/158/019 (112.5 mg, 2 pipettes) EU/2/13/158/022 (250 mg, 1 pipette) EU/2/13/158/023 (250 mg, 2 pipettes) EU/2/13/158/026 (500 mg, 1 pipette) EU/2/13/158/027 (500 mg, 2 pipettes)
Estonian: EU/2/13/158/018 (112,5 mg, 1 pipett) EU/2/13/158/019 (112,5 mg, 2 pipetti) EU/2/13/158/022 (250 mg, 1 pipett) EU/2/13/158/023 (250 mg, 2 pipetti) EU/2/13/158/026 (500 mg, 1 pipett) EU/2/13/158/027 (500 mg, 2 pipetti)
English: Can be used in breeding, pregnant and lactating dogs.
Estonian: Lubatud kasutada aretuses kasutatavatel, tiinetel ja lakteerivatel koertel.
English: In the absence of available data, the veterinary medicinal product should not be used on puppies less than 8 weeks old and /or dogs weighing less than 2 kg.
Estonian: Olemasolevate andmete puudumise tõttu ei tohi veterinaarravimit kasutada kutsikatel, kes on nooremad kui 8 nädala vanused ja/või koertel, kes kaaluvad vähem kui 2 kg.
English: The onset of effect is within 8 hours of attachment for fleas (C. felis) and 12 hours of attachment for ticks (I. ricinus).
Estonian: Toime kirpude (C. felis) vastu saabub 8 tunni jooksul kinnitumisest ning puukide (I. ricinus) vastu 12 tunni jooksul kinnitumisest.
English: Fluralaner was well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 3 times the maximum recommended dose (168 mg/kg bodyweight).
Estonian: Defektse multiravimiresistentse valguga 1 (MDR1 -/-) kollid talusid fluralaneeri hästi pärast ühekordset suukaudset manustamist kolmekordses soovitatavas annuses (168 mg/kg kehamassi kohta).
English: During laboratory and clinical field testing, no interactions between Bravecto spot-on solution for cats and routinely used veterinary medicinal products were observed.
Estonian: Välitingimustes läbiviidud laboratoorsetes ja kliinilistes uuringutes ei täheldatud koostoimeid kassidele mõeldud Bravecto täpilahuse ja tavakasutuses olevate veterinaarravimite vahel.
English: The onset of efficacy is within 8 hours for fleas (C. felis) and 12 hours for ticks (I. ricinus).
Estonian: Toime kirpude (C. felis) vastu saabub 8 tunni jooksul ja puukide (I. ricinus) vastu 12 tunni jooksul.
English: Bravecto should be administered in accordance with the following table (corresponding to a dose of 25-56 mg fluralaner/kg body weight):
Estonian: Bravectot tuleb manustada alltoodud tabeli järgi (vastavalt annusele 25-56 mg fluralaneeri kg kehamassi kohta).
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals
Estonian: Ettevaatusabinõud veterinaarravimit loomale manustavale isikule Selle ravimi allaneelamine on kahjulik.
English: The veterinary medicinal product was well tolerated in collies with a deficient multidrug-resistanceprotein 1 (MDR1 -/-) following single oral administration at 3 times the recommended dose.
Estonian: Defektse multiravimiresistentse valguga 1 (MDR1 -/-) kollid talusid veterinaarravimit hästi pärast ühekordset suukaudset manustamist kolmekordses soovitatavas annuses.
English: During laboratory and clinical field testing, no interactions between Bravecto spot-on solution for dogs and routinely used veterinary medicinal products were observed.
Estonian: Välitingimustes läbiviidud laboratoorsetes ja kliinilistes uuringutes ei täheldatud koostoimeid koertele mõeldud Bravecto täpilahuse ja tavakasutuses olevate veterinaarravimite vahel.
English: Soya-bean oil
Estonian: Sojaoaõli
English: for very small dogs 2 - 4.5 kg for small dogs >4.5 - 10 kg for medium-sized dogs >10 - 20 kg for large dogs >20 - 40 kg for very large dogs >40 - 56 kg
Estonian: väga väikestele koertele 2-4,5 kg väikestele koertele > 4,5-10 kg keskmise suurusega koertele > 10-20 kg suurtele koertele > 20-40 kg väga suurtele koertele > 40-56 kg
English: 5831 AN Boxmeer The NETHERLANDS
Estonian: Wim de Körverstraat 35 5831 AN Boxmeer Holland
English: for very small dogs (2-4.5 kg) for small dogs (>4.5-10 kg) for medium-sized dogs (>10-20 kg) for large dogs (>20-40 kg) for very large dogs (>40-56 kg)
Estonian: väga väikestele koertele (2-4,5 kg) väikestele koertele (> 4,5-10 kg) keskmistele suurusega koertele (> 10-20 kg) suurtele koertele (> 20-40 kg) väga suurtele koertele (> 40-56 kg)
English: Mild and transient gastrointestinal effects such as diarrhoea, vomiting, inappetence, and drooling were commonly observed in clinical trials (1.6% of treated dogs).
Estonian: Sagedased kõrvaltoimed kliinilistes uuringutes (1,6%-l ravitud koertest) olid kerged ja mööduvad seedetrakti nähud nagu diarröa, oksendamine, isutus ja süljevool.
English: Unit dose pipette made of laminated aluminium/polypropylene foil closed with an HDPE cap and packed in a laminated aluminium foil sachet.
Estonian: Ühe annusega pipett on valmistatud lamineeritud alumiinium/polüpropüleenfooliumist.
English: Mild and transient skin reactions at the application site such as erythema or alopecia were commonly observed in clinical trials (1.2% of treated dogs).
Estonian: Kliinilistes uuringutes olid sageli esinevad kõrvaltoimed kerged ja mööduvad nahareaktsioonid manustamiskohas (1,2%-l ravitud koertest), nagu erüteem või alopeetsia.
English: In the absence of available data, this veterinary medicinal product should not be used on puppies less than 8 weeks old and /or dogs weighing less than 2 kg.
Estonian: Olemasolevate andmete puudumise tõttu ei tohi seda veterinaarravimit kasutada alla 8 nädala vanustel kutsikatel ja/või alla 2 kg kehamassiga koertel.
English: Safety was demonstrated in kitten aged 11-13 weeks and weighing 1.2-1.5 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
Estonian: Üleannustamine (sümptomid, esmaabi, antidoodid) Ohutust näidati kassipoegadel vanuses 11-13 nädalat ja kehamassiga 1,2-1,5 kg, keda raviti maksimaalset soovitatavat annust kuni viis korda ületavate üleannustega kolmel korral soovitatavatest lühemate intervallidega (8-nädalaste intervallidega).
English: The product contributes towards the control of environmental flea populations in areas to which treated dogs have access.
Estonian: Veterinaarravim aitab kaasa kirbupopulatsioonide kontrolli all hoidmisele ravitud koertega kokkupuutuvas keskkonnas.
English: It is efficacious against ticks (Ixodes spp.)
Estonian: See on efektiivne kassil esinevate puukide (Ixodes spp) ning kirpude (Ctenocephalides spp) vastu.
English: The product contributes towards the control of environmental flea populations in areas to which treated cats have access.
Estonian: Veterinaarravim aitab kaasa kirbupopulatsioonide kontrolli all hoidmisele ravitud kassidega kokkupuutuvas keskkonnas.
English: Wear gloves when handling and administering this product.
Estonian: Ravimi käsitsemisel ja manustamisel kandke kaitsekindaid.
English: This veterinary medicinal product is a systemic insecticide and acaricide that provides: - immediate and persistent flea (Ctenocephalides felis and C. canis) killing activity for 12 weeks, - immediate and persistent tick (Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus) killing activity for 12 weeks.
Estonian: See veterinaarravim on süsteemne insektitsiid ja akaritsiid, millel on - kohene ja püsiv kirpe (Ctenocephalides felis ja C. canis) surmav toime 12 nädala jooksul; - kohene ja püsiv puuke (Ixodes ricinus, Rhipicephalus sanguineus ja Dermacentor reticulatus)
English: Overdose:
Estonian: Täppmanustamine.
English: Mild and transient skin reactions at the application site, such as erythema and pruritus or alopecia were commonly observed in clinical trials (2.2% of treated cats).
Estonian: Kliinilistes uuringutes olid sageli esinevad kõrvaltoimed kerged ja mööduvad nahareaktsioonid manustamiskohas (2,2%-l ravitud kassidest), nagu erüteem ja sügelus või alopeetsia.
English: Skin rashes tingling or numbness have been reported in a small number of individuals after skin contact.
Estonian: Pärast nahale sattumist on väikesel osal inimestest kirjeldatud nahalöövet, kihelust ja/või tuimust.
English: This veterinary medicinal product is a systemic insecticide and acaricide that provides: - immediate and persistent flea (Ctenocephalides felis and Ctenocephalides canis) killing activity for 12 weeks, and - immediate and persistent tick (Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus) killing activity for 12 weeks.
Estonian: See veterinaarravim on süsteemne insektitsiid ja akaritsiid, millel on - kohene ja püsiv kirpe (Ctenocephalides felis ja Ctenocephalides canis) surmav toime 12 nädala jooksul; - kohene ja püsiv puuke (Ixodes ricinus, Rhipicephalus sanguineus ja Dermacentor reticulatus)
English: No adverse reactions were observed following topical administration to kitten aged 11-13 weeks and weighing 1.2-1.5 kg treated with overdoses of up to 5 times the maximum recommended dose (93 mg, 279 mg and 465 mg fluralaner/kg body weight) on three occasions at shorter intervals than recommended (8-week intervals).
Estonian: Pärast paikset manustamist kassipoegadele vanuses 11-13 nädalat ja kehamassiga 1,2-1,5 kg, keda raviti maksimaalset soovitatavat annust kuni viis korda ületavate üleannustega (93 mg, 279 mg ja